GAITHERSBURG, Md., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced financial results for the fourth quarter and full year ...

Prior to Intercept, he spent over two decades in a variety of leadership roles at Sanofi, including Chief ... clinical trial materials on the timelines anticipated; and the success of future ...

While Syndax's stock has shown resilience in the face of regulatory timelines, the company's financial ... Analysts have drawn positive comparisons to Sanofi's Rezurock, which has shown strong ...

While Syndax's stock has shown resilience in the face of regulatory timelines, the company's financial performance ... Analysts have drawn positive comparisons to Sanofi's Rezurock, which has shown ...

He won’t give timelines about development of the drugs with Sanofi, which is still deciding ... on topics including regulation, mergers and acquisitions, and the latest clinical developments.

Based on previous success rates of ∼20%—and on typical development timelines of seven to eight ... such as Paris-based Sanofi-aventis, GlaxoSmithKline (GSK), Merck and Wyeth, of Madison ...

Fast-track designation and regulatory approvals speed up the timelines for drug development ... s advanced oligonucleotide chemistry platform. · In May 2024, Sanofi completed its acquisition of ...